ArticleMolecular and cellular biochemistry2026
Design, green synthesis, and anticancer evaluation of novel sulfaguanidine-based heterocycles as multi-target inhibitors of the VEGFR-2/PI3K/AKT/mTOR pathway.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pursuit of multi-target anticancer agents is a strategic approach to overcome drug resistance and improve selectivity. This study focuses on the design of novel heterocyclic compounds incorporating a sulfaguanidine moiety, targeting key pathways in cancer progression. A novel diazonium intermediate was synthesized from sulfaguanidine and used to prepare a series of pyrimidine and triazine derivatives 3-8 via both conventional and eco-friendly microwave techniques. All compounds were characterized by spectroscopic methods. The cytotoxic activity was evaluated against five human cancer cell lines (HEPG2, MCF7, A431, A375, and A549) and normal HSF fibroblasts. The mechanism of the lead compounds 3 and 4 was investigated through cell cycle analysis, qPCR analysis of VEGFR-2, PI3K, AKT, mTOR, Caspase-3, and CDC42 genes, and comprehensive molecular docking studies against the corresponding protein targets. ADMET profiles were also predicted. Microwave synthesis significantly improved reaction efficiency. Compounds 3 and 4 exhibited the most potent and selective cytotoxicity, with compound 4 showing activity against A431 cells (IC₅₀ = 4.87 µM). Mechanistic studies revealed compound 3 induced G2/M arrest, while Compound-4 caused G1 arrest. QPCR analysis confirmed significant downregulation of VEGFR-2, PI3K, AKT, mTOR, and CDC42, alongside upregulation of pro-apoptotic Caspase-3. Docking studies supported strong binding affinities to VEGFR-2, PI3K, AKT, and mTOR, correlating with the biological data. The integrated chemical and biological approach identified compounds 3 and 4 as promising multi-target agents. Their ability to disrupt angiogenesis, survival signaling, and cell cycle progression, while inducing apoptosis, highlights their potential as lead compounds for further anticancer development.
Indexed as
Identifiers
42803866What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.